Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 25, 2022

Dapagliflozin for Heart Failure According to BMI

European Heart Journal


Additional Info

European Heart Journal
Dapagliflozin for heart failure according to body mass index: the DELIVER trial
Eur Heart J 2022 Aug 27;[EPub Ahead of Print], C Adamson, T Kondo, P Jhund, RA de Boer, JWC Honorio, B Claggett, AS Desai, MAA Gamba, W Al Habeeb, AF Hernandez, SE Inzucchi, MN Kosiborod, CSP Lam, AM Langkilde, D Lindholm, E Bachus, SE Litwin, F Martinez, M Petersson, SJ Shah, M Vaduganathan, PN Vinh, U Wilderäng, SD Solomon, JJ McMurray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading